Loading...

Mirati Therapeutics, Inc.

MRTXNASDAQ
Healthcare
Biotechnology
$58.70
$-0.10(-0.17%)

Mirati Therapeutics, Inc. MRTX Peers

See (MRTX) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
MRTX$58.70-0.17%4.1B-4.82-$12.18N/A
VRTX$459.62+0.57%118B-119.69-$3.84N/A
REGN$547.36-0.07%58.1B13.91$39.35+0.16%
ALNY$331.91+0.65%43.3B-157.30-$2.11N/A
SGEN$228.74-0.07%43.2B-57.19-$4.00N/A
ARGX$543.48-0.30%33.2B33.16$16.39N/A
BNTX$110.00+1.61%26.4B-30.05-$3.66N/A
RPRX$36.37+0.50%20.5B14.84$2.45+2.36%
BGNE$184.71+0.49%20.2B-22.55-$8.19N/A
DNA-WT$0.27-2.76%18.7BN/AN/AN/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

MRTX vs VRTX Comparison

MRTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MRTX stands at 4.1B. In comparison, VRTX has a market cap of 118B. Regarding current trading prices, MRTX is priced at $58.70, while VRTX trades at $459.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MRTX currently has a P/E ratio of -4.82, whereas VRTX's P/E ratio is -119.69. In terms of profitability, MRTX's ROE is -0.62%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, MRTX is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for MRTX.

Stock Price Comparison

Loading...

Frequently Asked Questions

;